Nearly three months after Quintiles Transnational Corp. Chairman Dennis Gillings announced his $1.3 billion intent to buy the company, the Street remains confident of a richer price. Some sources, though, nixed the chance of other bidders stepping up for Quintiles. On Oct. 14, Gillings, chairman of Quintiles for two decades, made a non-binding $11.25-per-share cash squeeze-out offer for the company. Gillings owns 5.5% of Research Triangle Park, N.C.-based Quintiles, a contract research provider to pharmaceutical, medical device and biotechnology companies.
To read the entire story, you must be logged in.
Please log in now or register with us.
